Literature DB >> 24509231

Is cancer vaccination feasible at older age?

Claudia Gravekamp1, Arthee Jahangir2.   

Abstract

Age-related defects of the immune system are responsible for T cell unresponsiveness to cancer vaccination at older age. Major immune defects at older age are lack of naive T cells, impaired activation pathways of T cells and antigen-presenting cells (APCs), and age-related changes in the tumor microenvironment (TME). This raises the question whether cancer vaccination is feasible at older age. We compared various cancer vaccine studies at young and old age, thereby focusing on the importance of both innate and adaptive immune responses for cancer immunotherapy. These analyses suggest that creating an immune-stimulating environment with help of the innate immune system may improve T cell responses in cancer vaccination at older age. Published by Elsevier Inc.

Entities:  

Keywords:  Adaptive immune system; Aging; Cancer immunotherapy; Cancer vaccines; Immune system; Innate immune system

Mesh:

Substances:

Year:  2014        PMID: 24509231      PMCID: PMC4053252          DOI: 10.1016/j.exger.2014.01.025

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  81 in total

Review 1.  Impact of aging on dendritic cell functions in humans.

Authors:  Anshu Agrawal; Sudhir Gupta
Journal:  Ageing Res Rev       Date:  2010-07-07       Impact factor: 10.895

2.  A new mechanism for blocking myeloid-derived suppressor cells by CpG.

Authors:  Melissa G Lechner; Alan L Epstein
Journal:  Clin Cancer Res       Date:  2011-02-02       Impact factor: 12.531

3.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer.

Authors:  Wilber Quispe-Tintaya; Dinesh Chandra; Arthee Jahangir; Matthew Harris; Arturo Casadevall; Ekaterina Dadachova; Claudia Gravekamp
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

6.  Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.

Authors:  Eva Schlecker; Ana Stojanovic; Christian Eisen; Christian Quack; Christine S Falk; Viktor Umansky; Adelheid Cerwenka
Journal:  J Immunol       Date:  2012-11-14       Impact factor: 5.422

7.  Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice.

Authors:  Victoria Jeisy-Scott; William G Davis; Jenish R Patel; John Bradford Bowzard; Wun-Ju Shieh; Sherif R Zaki; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  PLoS One       Date:  2011-09-23       Impact factor: 3.240

8.  Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.

Authors:  Manisha Singh; Ilyssa Ramos; Denise Asafu-Adjei; Wilber Quispe-Tintaya; Dinesh Chandra; Arthee Jahangir; Xingxing Zang; Bharat B Aggarwal; Claudia Gravekamp
Journal:  Cancer Med       Date:  2013-07-02       Impact factor: 4.452

9.  Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice.

Authors:  D Chandra; A Jahangir; W Quispe-Tintaya; M H Einstein; C Gravekamp
Journal:  Br J Cancer       Date:  2013-05-02       Impact factor: 7.640

10.  Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer.

Authors:  Chris P Verschoor; Jennie Johnstone; Jamie Millar; Michael G Dorrington; Mojtaba Habibagahi; Alina Lelic; Mark Loeb; Jonathan L Bramson; Dawn M E Bowdish
Journal:  J Leukoc Biol       Date:  2013-01-22       Impact factor: 4.962

View more
  5 in total

1.  Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes.

Authors:  Scott M J Cornwall; Matthew Wikstrom; Arthur W Musk; John Alvarez; Anna K Nowak; Delia J Nelson
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

2.  Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms.

Authors:  Arthee Jahangir; Dinesh Chandra; Wilber Quispe-Tintaya; Manisha Singh; Benson Chellakkan Selvanesan; Claudia Gravekamp
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

3.  Loss of Phagocytic and Antigen Cross-Presenting Capacity in Aging Dendritic Cells Is Associated with Mitochondrial Dysfunction.

Authors:  Claire A Chougnet; Robert I Thacker; Hesham M Shehata; Cassandra M Hennies; Maria A Lehn; Celine S Lages; Edith M Janssen
Journal:  J Immunol       Date:  2015-08-05       Impact factor: 5.422

4.  Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span.

Authors:  Mauro Provinciali; Alessandra Barucca; Fiorenza Orlando; Elisa Pierpaoli
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

Review 5.  Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity.

Authors:  Regina E M Baiden-Amissah; Sandra Tuyaerts
Journal:  Int J Mol Sci       Date:  2019-07-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.